1996-1998 / University of North Carolina, Chapel Hill, Fellowship, Nephrology
1995-1996 / University of North Carolina, Chapel Hill, Chief Resident, Internal Medicine
1993-1995 / University of North Carolina, Chapel Hill, Residency, Internal Medicine
1988-1992 / Georgetown University, Doctor of Medicine
1984-1988 / Georgetown University, Bachelor of Science
Work Experience
1998-Present / Clinical Nephrologist, Mountain Kidney and Hypertension Associates, PA
1996-1998 / Fellow in Nephrology, University of North Carolina, Chapel Hill
1993-1996 / Medical Residency, Internal Medicine, University of North Carolina, Chapel Hill
Credentials
Medical License: North Carolina Physician License / 9500006
Certification: North Carolina Medical Board / 54659
American Board of Internal Medicine, 1996, 2006, 2016
American Board of Nephrology, 1999, 2008, 2018
Hospital Affiliations
1998-Present
Mission-St. Joseph's Health System
509 Biltmore Avenue
Asheville, NC 28801-4690
Professional Affiliations / Committees
Adjunct Professor, Department of Medicine, UNC School of Medicine, Chapel Hill
Asheville Specialty Hospital - Medical Executive Committee
American Society of Nephrology
American Society for Apheresis
National Kidney Foundation
Renal Physicians Association
North Carolina Medical Society
Training
National Institutes of Health “Protecting Human Research Participants”
07/13/2009, Certificate #255968
09/26/2012, Certificate #1012544
08/12/2014, Certificate #1516437
CITI – Human Research for Biomedical Research Investigators, 09/26/2012, 08/12/2014
CITI – Good Clinical Practice, 08/14/2014, 09/06/2016, 11/18/2018
Research
Sub-Investigator
Trial to Reduce Cardiovascular Events with Aranesp Therapy
Principal Investigator
A Phase 4, Long-Term Observational Safety Study in End Stage Renal Disease Subjects Treated with Fosrenol
Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using GENZ-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis
Principal Investigator
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease
Principal Investigator
A Phase 3, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated with Epoetin
Principal Investigator
A Phase 3, Randomized, Active-Controlled, Open-Label Study of the Safety and Efficacy of AF37702 Injection for the Correction of Anemia in Patients with Chronic Renal Failure not on Dialysis and not on Erythropoiesis Stimulating Agent (ESA) Treatment
Principal Investigator
A Randomized Evaluation of the Efficacy and Safety of Ferric Carboxymaltose in Patients with Iron Deficiency Anemia and Impaired Renal Function
Principal Investigator
A Four Week, Phase IIa, Randomized, double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK1278863 in Subjects with Anemia Associated with Chronic Kidney Disease Who Are Not Taking Recombinant Human Erythropoietin and Are Not Undergoing Dialysis
Principal Investigator
A Four-Week, Phase IIa, Randomized, Active-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-Dependent Subjects with Anemia Associated with Chronic Kidney Disease
Principal Investigator
A Phase II, Randomized, Open-Label, Dose Titration, Efficacy and Safety Study of FGCL-4592 in Non-Dialysis Chronic Kidney Disease Patients with Anemia
Principal Investigator
An Open-Label, Extension Study to Evaluate the Efficacy and Safety of FGCL-4592 for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients with Chronic Kidney Disease
Principal Investigator
Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type II Diabetes: The Occurrence of Renal Events (BEACON)
Principal Investigator
START-CKD: Strategies Using Darbepoetin alfa to Avoid Transfusions in Chronic Kidney Disease
Sub-Investigator
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects with Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Sub-Investigator
A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects with Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)
Principal Investigator
Qualitative Interviews with Diabetic Kidney Disease Patients
Principal Investigator
A 16-week, Phase 2a, single-arm, multi-center, open-label study to evaluate the safety and efficacy of GSK1278863 after switching from recombinant human erythropoietin (rhEPO), in hemodialysis-dependent subjects with anemia associated with chronic kidney disease who are chronically hyporesponsive to rhEPO.
Principal Investigator
A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy (CREDENCE)
Principal Investigator
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI 2690B Injection in Patients with Nephropathy Due to Diabetes
Principal Investigator
A Phase 2 Dose-ranging, Double-blind, Placebo-controlled Study Evaluating the Efficacy, Safety and Tolerability of GS-4997 on Subjects with Stage 3 or Stage 4 Diabetic Kidney Disease
Sub Investigator
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin™ (pyridoxamine dihydrochloride) in Subjects with Nephropathy Due to Type 2 Diabetes
Principal Investigator
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
Principal Investigator
A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of dapradustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents
Principal Investigator
A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
Principal Investigator
Impact of Advance Care Planning Coaching for Patients with Chronic Kidney Disease (Making Your Wishes About You)
Principal Investigator
A 28-week, randomized, double-blind, placebo-controlled, parallel group, multi-center, study in recombinant human erythropoietin (rhEPO) naïve non-dialysis participants with anemia associated with chronic kidney disease to evaluate the efficacy, safety and effects on quality of life of daprodustat compared to placebo.
Principal Investigator
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
Principal Investigator
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease
Principal Investigator
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease
Principal Investigator
A multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease (EMPA-CKD)
Principal Investigator
Global Kidney Patients Trial Network
Principal Investigator
A Phase IIb Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With IgA Nephropathy (Origin)
Publications
Robert Provenzano, Anatole Besarab, Chao H. Sun, Susan A Diamond, John H. Durham, Jose L. Cangiono, Joseph R. Aiello, James E. Novak, Tyson Lee, Robert Leong, Brian K. Roberts, Khalil G. Saikali, Stefan Hemmerich, Lynda A. Szczech, Kin-Hung Peony Yu, and Thomas B. Neff. “Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.” Clinical Journal of American Society of Nephrology 11 (2016): 982-991.
